imatinib mesylate has been researched along with Benign Monoclonal Gammopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dourado, C; Gupta, S; Swaminathan, N | 1 |
| Lu, S; Ouyang, W; Wang, Z; Zhao, X | 1 |
2 other study(ies) available for imatinib mesylate and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Thalidomide | 2020 |
Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report.
Topics: Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Mutation; Positive Regulatory Domain I-Binding Factor 1; Prednisolone; Prevalence; Thalidomide; Treatment Outcome | 2018 |